Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.660
+0.050 (3.11%)
At close: Aug 21, 2026, 4:00 PM EDT
1.679
+0.019 (1.15%)
After-hours: Aug 21, 2026, 7:30 PM EDT

Caribou Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
10.0411.169.9934.4813.859.6
Revenue Growth
10.02%11.66%-71.01%148.91%44.31%-22.35%
Cost of Revenue
83.85107.52130.15112.0882.2352.26
Gross Profit
-73.82-96.36-120.16-77.6-68.38-42.66
Selling, General & Admin
33.3837.5546.4638.4638.0224.32
Operating Expenses
33.3837.5546.4638.4638.0224.32
Operating Income
-107.2-133.92-166.62-116.06-106.4-66.98
Interest & Investment Income
4.69815.315.3--
Earnings From Equity Investments
--9.16----
Other Non Operating Income (Expenses)
0.830.832.2-1.127.18-1.21
EBT Excluding Unusual Items
-101.68-134.25-149.11-101.88-99.22-68.19
Merger & Restructuring Charges
-2.28-2.28----
Gain (Loss) on Sale of Investments
-----0.13-
Asset Writedown
--12.15----
Other Unusual Items
-----1.58
Pretax Income
-103.95-148.68-149.11-101.88-99.35-66.6
Income Tax Expense
-0.55-0.55-0.010.190.070.32
Net Income
-103.4-148.13-149.11-102.07-99.42-66.92
Net Income to Common
-103.4-148.13-149.11-102.07-99.42-66.92
Net Income Growth
------
Shares Outstanding (Basic)
969390746132
Shares Outstanding (Diluted)
969390746132
Shares Change
4.73%3.40%22.37%21.39%92.02%270.47%
EPS (Basic)
-1.08-1.59-1.65-1.38-1.64-2.11
EPS (Diluted)
-1.08-1.59-1.65-1.38-1.64-2.11
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-95.75-112.35-143.08-104.9-97.42-34.64
Free Cash Flow Per Share
-1.00-1.20-1.58-1.42-1.60-1.09
Gross Margin
----225.07%--
Operating Margin
-1068.22%-1200.09%-1667.16%-336.63%-768.17%-697.84%
Profit Margin
-1030.42%-1327.40%-1491.94%-296.05%-717.79%-697.26%
Free Cash Flow Margin
-954.18%-1006.82%-1431.66%-304.27%-703.34%-360.91%
EBITDA
-104.61-130.27-162.69-112.53-104.78-66
D&A For EBITDA
2.593.653.933.531.620.98
EBIT
-107.2-133.92-166.62-116.06-106.4-66.98
SEC Filings: 10-K · 10-Q